This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
|Articles|November 6, 2008
EMEA Recommends Rx-to-OTC Switch for Orlistat
Author(s)Patricia Van Arnum
The European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use recommended that the status of GlaxoSmithKline's anti-obesity drug "Alli" (orlistat) be switched from prescription-only to nonprescription.
Advertisement
London (Oct. 23)-The European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) recommended that the status of GlaxoSmithKline’s (GSK, London) anti-obesity drug “Alli” (orlistat) be switched from prescription-only to nonprescription. This change marks the first time that EMEA has recommended that the status for supply of a centrally authorized medicine in the European Union be switched from prescription-only to nonprescription, according to EMEA.
EMEA recommended the switch as part of an extension of the marketing authorization in response to an application by the marketing-authorization holder for a lower-dose capsule (60 mg) with a new classification as a nonprescription medicine. Alli (60 mg) is used in conjunction with dieting for treating overweight patients who have a body mass index of 28 or above.
“This is the first time a nonprescription product has been centrally reviewed and given a positive opinion by the CHMP,” said John Clarke, president of GSK Consumer Healthcare, in a company press release. “This is a real testimony to the strength and regulatory expertise that GSK has within the consumer-healthcare arena.”
Following review of the required data for Alli (60 mg), the CHMP concluded that the switch could be recommended because of the following:
• The 60-mg dose was effective in helping patients to lose weight when taken in conjunction with dieting
• Its side effects were milder than those with the existing 120-mg dose
• The package leaflet and the label will enable patients to use the medicine correctly and appropriately.
The CHMP’s recommendation will be sent to the European Commission for the adoption of the decision.
Pending approval, which could be granted by the end of 2008, GSK says that it anticipates launching the product in 2009 as the first licensed weight-loss treatment available without a prescription.
For further information on EMEA’s guideline on changing the classification for the supply of a medicinal product for human use, click
.
For more information on Alli, see the European public assessment
Advertisement
Related to this article
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Advertisement
Advertisement